Thiogenesis Announces European Consulting and Investor Relations Agreement
Thiogenesis Therapeutics (TSXV: TTI) (OTCQX: TTIPF), a clinical-stage biotech company, has entered into a consulting and investor relations agreement with Bull Markets Media GmbH, effective February 15, 2025. The German-based digital stock market news portal will analyze opportunities to expand the company's European shareholder base and network.
The agreement includes a C$60,000 consulting fee, with 50% payable upon signing and the remainder due June 1, 2025. Additionally, the consultant will receive 100,000 stock options at $0.64 per share, valid for 3 years, vesting in four equal tranches of 25,000 between May 2025 and February 2026. The 12-month agreement can be renewed annually for up to two additional years.
The TSXV has also given final acceptance of Thiogenesis's IR contract with Triomphe Holdings (Capital Analytica).
Thiogenesis Therapeutics (TSXV: TTI) (OTCQX: TTIPF), una compagnia biotech in fase clinica, ha stipulato un accordo di consulenza e relazioni con gli investitori con Bull Markets Media GmbH, con effetto dal 15 febbraio 2025. Il portale tedesco di notizie sul mercato azionario digitale analizzerà le opportunità per espandere la base azionaria e la rete dell'azienda in Europa.
L'accordo prevede un
Il TSXV ha anche dato accettazione finale del contratto IR di Thiogenesis con Triomphe Holdings (Capital Analytica).
Thiogenesis Therapeutics (TSXV: TTI) (OTCQX: TTIPF), una compañía biotecnológica en etapa clínica, ha firmado un acuerdo de consultoría y relaciones con inversores con Bull Markets Media GmbH, efectivo a partir del 15 de febrero de 2025. El portal alemán de noticias del mercado de valores digitales analizará las oportunidades para expandir la base de accionistas y la red de la compañía en Europa.
El acuerdo incluye una
El TSXV también ha dado la aceptación final del contrato de IR de Thiogenesis con Triomphe Holdings (Capital Analytica).
Thiogenesis Therapeutics (TSXV: TTI) (OTCQX: TTIPF), 임상 단계의 생명공학 회사가 Bull Markets Media GmbH와 2025년 2월 15일부터 유효한 자문 및 투자자 관계 계약을 체결했습니다. 독일에 본사를 둔 디지털 주식 시장 뉴스 포털은 회사의 유럽 주주 기반 및 네트워크 확장 기회를 분석할 예정입니다.
계약에는 C$60,000의 자문료가 포함되어 있으며, 50%는 서명 시 지급되고 나머지는 2025년 6월 1일에 지급됩니다. 또한, 자문가는 100,000주식 옵션을 주당 $0.64에 받으며, 3년 동안 유효하고 2025년 5월과 2026년 2월 사이에 25,000개씩 4개의 동일한 분할로 배정됩니다. 12개월 계약은 최대 2년까지 매년 갱신할 수 있습니다.
TSXV는 또한 Thiogenesis의 Triomphe Holdings (Capital Analytica)와의 IR 계약에 대한 최종 승인을 부여했습니다.
Thiogenesis Therapeutics (TSXV: TTI) (OTCQX: TTIPF), une entreprise biopharmaceutique en phase clinique, a signé un accord de consultation et de relations avec les investisseurs avec Bull Markets Media GmbH, en vigueur à partir du 15 février 2025. Le portail allemand d'actualités sur le marché boursier numérique analysera les opportunités d'élargir la base d'actionnaires et le réseau de l'entreprise en Europe.
L'accord comprend un honoraire de consultation de 60 000 $ CA, dont 50 % sont payables à la signature et le reste dû le 1er juin 2025. De plus, le consultant recevra 100 000 options d'achat d'actions à 0,64 $ par action, valables pendant 3 ans, avec un vesting en quatre tranches égales de 25 000 entre mai 2025 et février 2026. L'accord de 12 mois peut être renouvelé chaque année pour un maximum de deux années supplémentaires.
La TSXV a également donné son approbation finale au contrat IR de Thiogenesis avec Triomphe Holdings (Capital Analytica).
Thiogenesis Therapeutics (TSXV: TTI) (OTCQX: TTIPF), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat einen Beratungs- und Investorenbeziehungsvertrag mit Bull Markets Media GmbH abgeschlossen, der am 15. Februar 2025 in Kraft tritt. Das in Deutschland ansässige digitale Nachrichtenportal für den Aktienmarkt wird Möglichkeiten zur Erweiterung der europäischen Aktionärsbasis und des Netzwerks des Unternehmens analysieren.
Der Vertrag umfasst ein Beraterhonorar von C$60.000, von dem 50% bei Vertragsunterzeichnung fällig sind, der Rest bis zum 1. Juni 2025. Darüber hinaus erhält der Berater 100.000 Aktienoptionen zu einem Preis von 0,64 $ pro Aktie, die für 3 Jahre gültig sind und in vier gleichen Tranchen von 25.000 zwischen Mai 2025 und Februar 2026 fällig werden. Der 12-monatige Vertrag kann jährlich um bis zu zwei zusätzliche Jahre verlängert werden.
Die TSXV hat zudem die endgültige Genehmigung des IR-Vertrags von Thiogenesis mit Triomphe Holdings (Capital Analytica) erteilt.
- None.
- Issuance of 100,000 stock options represents potential dilution for existing shareholders
- C$60,000 consulting fee adds to operational expenses
San Diego, California--(Newsfile Corp. - February 20, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides that drive the production of critically important intracellular antioxidants and other therapeutic compounds, today announced that it has entered into a consulting and investor relations agreement effective February 15, 2025 (the "Agreement") with Bull Markets Media GmbH (the "Consultant"), a Germany-based digital stock market news portal.
The services to be provided by the Consultant include analyzing and assessing opportunities to broaden the Company's shareholder base and expanding the Company's contact network within Europe.
Pursuant to the Agreement, the Company has agreed to pay the Consultant a consulting fee of C
The Company and the Consultant act at arm's length and the Consultant has no present interest, directly or indirectly, in the Company or its securities. The Agreement and its terms, including the grant of stock options, are subject to acceptance by the TSX Venture Exchange.
The Company is also pleased to announce that the TSXV has issued final acceptance of the Company's IR contract with Triomphe Holdings Ltd. doing business as Capital Analytica (see the Company's news release dated September 27, 2024).
About Thiogenesis
Thiogenesis Therapeutics, Corp. is a clinical-stage biopharmaceutical company operating through its wholly owned subsidiary based in San Diego, CA. Thiogenesis is developing sulfur-containing prodrugs that act as precursors to previously approved thiol-active compounds, with the potential to treat serious pediatric diseases with unmet medical needs. Prodrugs are drugs that contain previously approved active ingredients and are modified so that they only become active when metabolized. For regulatory purposes prodrugs can use existing third-party safety data in regulatory submissions in the streamlined 505 (b)(2) regulatory pathway in the US, and its equivalent hybrid system in Europe, to proceed into human efficacy trials with regulatory clearance. Prodrugs may enhance the profile of the active ingredient to increase its bioavailability and reduce side effects. Initial target indications include Mitochondrial Encephalopathy Lactic Acidosis and Stroke ("MELAS"), Leigh syndrome, Rett syndrome and pediatric MASH.
For further information, please contact:
Brook Riggins, Director, and CFO
Email: info@thiogenesis.com
Tel.: (888) 223-9165
Forward Looking Statements
This news release contains certain forward-looking statements and forward-looking information (collectively referred to herein as "forward-looking statements") within the meaning of Canadian securities laws including, without limitation, statements with respect to the future investments by the Company. All statements other than statements of historical fact are forward-looking statements. Undue reliance should not be placed on forward-looking statements, which are inherently uncertain, are based on estimates and assumptions, and are subject to known and unknown risks and uncertainties (both general and specific) that contribute to the possibility that the future events or circumstances contemplated by the forward-looking statements will not occur. Although the Company believes that the expectations reflected in the forward-looking statements contained in this press release, and the assumptions on which such forward-looking statements are made, are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking statements included in this document, as there can be no assurance that the plans, intentions, or expectations upon which the forward-looking statements are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause the Company's actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, except as required by applicable law. The forward-looking statements contained herein are expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange, nor the OTC Markets Group Inc. (OTCQX: OTCM) accepts responsibility for the adequacy or accuracy of this news release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/241481
FAQ
What are the terms of Thiogenesis (TTIPF) stock options granted to Bull Markets Media?
How much is Thiogenesis (TTIPF) paying Bull Markets Media for consulting services?
What is the duration of Thiogenesis (TTIPF) agreement with Bull Markets Media?
What services will Bull Markets Media provide to Thiogenesis (TTIPF)?
